Stock EYPT EYEPOINT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 03:29:14 2024-05-23 pm EDT 		5-day change 1st Jan Change
11.22 USD -2.22% Intraday chart for EyePoint Pharmaceuticals, Inc. -11.02% -51.80%
May. 08 Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating MT
May. 08 Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M MT

Business Summary

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.

Number of employees: 121

Sales per Business

USD in Million2022Weight2023Weight Delta
License and Collaboration Agreements
66.9 %
0 0.9 % 31 66.9 % +8,407.46%
Ophthalmic Products
30.9 %
40 96.4 % 14 30.9 % -64.34%
Royalty
2.1 %
1 2.7 % 1 2.1 % -13.02%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
98.4 %
40 97.8 % 45 98.4 % +11.83%
China
1.4 %
1 2.0 % 1 1.4 % -21.26%
United Kingdom
0.2 %
0 0.2 % 0 0.2 % 0.00%

Managers

Managers TitleAgeSince
Jay Duker CEO
 Chief Executive Officer 66 16-09-26
George Elston DFI
 Director of Finance/CFO 59 19-11-13
Said Saim CTO
 Chief Tech/Sci/R&D Officer 66 19-06-09
Jennifer Leonard CTO
 Chief Tech/Sci/R&D Officer - -
Nancy Lurker BRD
 Director/Board Member 66 16-09-14
Isabelle Lefebvre LAW
 General Counsel - 22-03-06
Michael Pine PRN
 Corporate Officer/Principal - 22-01-06
Scott Jones PRN
 Corporate Officer/Principal 57 19-06-09
Ron I. Honig LAW
 General Counsel - 18-11-26

Members of the board

Members of the board TitleAgeSince
Jay Duker CEO
 Chief Executive Officer 66 16-09-26
Wendy DiCicco BRD
 Director/Board Member 56 19-07-14
David Guyer BRD
 Director/Board Member 64 19-01-24
Anthony Adamis BRD
 Director/Board Member 65 22-06-22
Nancy Lurker BRD
 Director/Board Member 66 16-09-14
Göran Albert Ando CHM
 Chairman 75 18-06-26
John Landis BRD
 Director/Board Member 71 18-10-24
Karen Zaderej BRD
 Director/Board Member 62 22-07-10
Stuart Duty BRD
 Director/Board Member 59 23-10-15
Ye Liu BRD
 Director/Board Member 53 20-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 52,084,375 50,764,738 ( 97.47 %) 0 97.47 %

Shareholders

NameEquities%Valuation
Cormorant Asset Management LP
15.98 %
8,325,000 15.98 % 135 M $
Cormorant Asset Management LP
13.23 %
6,893,235 13.23 % 111 M $
Adage Capital Management LP
9.900 %
5,156,299 9.900 % 83 M $
Adage Capital Partners GP LLC
9.132 %
4,756,299 9.132 % 77 M $
Suvretta Capital Management LLC
7.227 %
3,763,888 7.227 % 61 M $
Fiduciary Trust Company International
6.507 %
3,389,237 6.507 % 55 M $
BlackRock Advisors LLC
5.004 %
2,606,288 5.004 % 42 M $
T. Rowe Price International Ltd.
4.734 %
2,465,815 4.734 % 40 M $
Vanguard Fiduciary Trust Co.
4.601 %
2,396,228 4.601 % 39 M $
Millennium Management LLC
3.929 %
2,046,438 3.929 % 33 M $

Company contact information

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street Suite A-210

02472, Watertown

+617 926 5000

http://www.eyepointpharma.com
address EyePoint Pharmaceuticals, Inc.(EYPT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for EyePoint Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
11.47 USD
Average target price
39.11 USD
Spread / Average Target
+240.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
EYEPOINT PHARMACEUTICALS, INC. Stock EyePoint Pharmaceuticals, Inc.
-51.80% 597M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.37% 723B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.28% 595B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.41% 369B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.08% 332B
ABBVIE INC. Stock AbbVie Inc.
+2.51% 282B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 244B
NOVARTIS AG Stock Novartis AG
+9.31% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-5.07% 205B
PFIZER, INC. Stock Pfizer, Inc.
-0.07% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. EYPT Stock
  4. Company EyePoint Pharmaceuticals, Inc.